Home >

Welcome to Molecular Oncology Tumor Boards

The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more. 

To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
May 11, 2016 9:46 AM
Read more to answer the following questions: 1) Would further imaging be required before discussing a plan for systemic therapy?  2) Which of the available tissue specimen/sites would be appropriate for HER2 testing: tissue from the primary resection specimen, metastasis from the para-aortic lymph...
Molecular Oncology Tumor Board
ASCO University
Apr 13, 2016 9:33 AM
Read more to answer the following questions: 1) What are available second line therapy options? 2)  Do you test for PD-L1 prior to recommending therapy? 3) Does smoking history affect your treatment recommendations?
Molecular Oncology Tumor Board
ASCO University
Mar 09, 2016 9:36 AM
Read more to answer the following questions: 1) What molecular testing on tissue should be performed in newly diagnosed DLBCL? 2) How need for molecular testing affects tissue requirements and biopsy size? 3) What staging studies and serum biomarkers would you obtain?  
Molecular Oncology Tumor Board
ASCO University
Feb 10, 2016 9:49 AM
Read more to answer the following questions: 1) Choice for site of biopsy? LN vs. Bone and merits/pros/cons for tissue for molecular profiling vs. confirmation of distant recurrence? 2) Would you recommend clinical genetics consultation for BRCA testing?  Expanded panel testing? 3) What additional...
Molecular Oncology Tumor Board
ASCO University
Jan 13, 2016 9:19 AM
Read more to answer the following questions: 1) What are the pathologic features that distinguish PEComa from the much more common leiomyosarcoma? 2) What is the role for cytotoxic chemotherapy in the treatment of metastatic or unresectable PEComa? 3) Are there any particular genetic targets...

Pages


Advertisement